Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Assets (2019 - 2025)

Historic Assets for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $26.4 million.

  • China SXT Pharmaceuticals' Assets fell 1498.21% to $26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.4 million, marking a year-over-year decrease of 1498.21%. This contributed to the annual value of $21.7 million for FY2025, which is 632.83% down from last year.
  • As of Q3 2025, China SXT Pharmaceuticals' Assets stood at $26.4 million, which was down 1498.21% from $21.7 million recorded in Q1 2025.
  • In the past 5 years, China SXT Pharmaceuticals' Assets ranged from a high of $34.5 million in Q1 2021 and a low of $14.6 million during Q3 2023
  • Moreover, its 5-year median value for Assets was $24.7 million (2024), whereas its average is $25.9 million.
  • In the last 5 years, China SXT Pharmaceuticals' Assets tumbled by 3423.31% in 2023 and then surged by 11248.56% in 2024.
  • China SXT Pharmaceuticals' Assets (Quarter) stood at $22.7 million in 2021, then dropped by 2.16% to $22.2 million in 2022, then tumbled by 34.23% to $14.6 million in 2023, then skyrocketed by 112.49% to $31.0 million in 2024, then decreased by 14.98% to $26.4 million in 2025.
  • Its Assets stands at $26.4 million for Q3 2025, versus $21.7 million for Q1 2025 and $31.0 million for Q3 2024.